Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 292.

https://doi.org/10.1182/blood-2023-182967

Published: 2023

Journal Articles

Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

Blood (2023) 142 (1): 44–61.

https://doi.org/10.1182/blood.2022017230

Published: 2023

Includes: Supplemental data

Journal Articles

The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib

Adam S. Kittai, Cecelia Miller, Daniel Goldstein, Ying Huang, Lynne V. Abruzzo, Kyle Beckwith, Seema A. Bhat, David A. Bond, Michael R. Grever, Nyla A. Heerema, Kerry A. Rogers, Amy S. Ruppert, John C. Byrd, Jennifer A. Woyach

Blood (2021) 138 (23): 2372–2382.

https://doi.org/10.1182/blood.2020010536

Published: 2021

Includes: Supplemental data

Journal Articles

Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status

Cecelia Miller, Ying Huang, Jonathan Hyak, Matthew R Avenarius, Amy S. Ruppert, John C. Byrd, Seema A Bhat, Michael R Grever, Adam S Kittai, Kerry Rogers, Nyla A. Heerema, Lynne V. Abruzzo, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2021-150722

Published: 2021

Journal Articles

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Seema A Bhat, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Nyla A Heerema, PhD, Lynne V. Abruzzo, MD PhD, Cecelia Miller, PhD, Jennifer Zvosec, CCRP, Kasturi Ganesh-Barki, MBBS, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-138612

Published: 2020

Journal Articles

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Daniel Goldstein, MD, Kyle A. Beckwith, MDPhD, Cecelia Miller, PhD, Ying Huang, MS, MA, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, David A. Bond, MD, John C. Byrd, MD, Michael R. Grever, MD, Nyla A Heerema, PhD, Kerry A. Rogers, MD, Amy S. Ruppert, PhD, Jennifer A. Woyach, MD, Adam S. Kittai, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136714

Published: 2020

Journal Articles

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, Corinne Hoffman, MS, CNP, Kami J. Maddocks, MD, Gerard Lozanski, MD, Adam S. Kittai, MD, Mollie E. Moran, Mark Reid, CNP, Jennifer A. Woyach, MD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137655

Published: 2020

Journal Articles

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia

Blood (2019) 134 (8): 688–698.

https://doi.org/10.1182/blood.2019000490

Published: 2019

Includes: Supplemental data

Journal Articles

Intricacies of CLL cytogenetic complexity

Lynne V. Abruzzo

Blood (2019) 133 (11): 1168–1170.

https://doi.org/10.1182/blood-2019-01-896068

Published: 2019

Journal Articles

Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events

Dan Jones, MD PhD, Huolin Tu, PhD, Jennifer A. Woyach, MD, Kerry A. Rogers, MD, Xiaokang Pan, PhD, Susan Long, Brianna Sisson, Sean Caruthers, Peng Ru, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Lynne V. Abruzzo, MD PhD, Weiqiang Zhao, MD PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2018-99-116293

Published: 2018

Journal Articles

Aberrant Methylation and Decreased Expression of NRIP1 in IGHV -Unmutated CLL

Madelyn Gerber, PhD, Yali Zhu, PhD, Yue-Zhong Wu, MAS, Brian Giacopelli, BS, Kevin Coombes, PhD, Christopher C Oakes, PhD, Lynne V. Abruzzo, MD PhD

Blood (2016) 128 (22): 1527.

https://doi.org/10.1182/blood.V128.22.1527.1527

Published: 2016

Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Blood (2016) 128 (22): 55.

https://doi.org/10.1182/blood.V128.22.55.55

Published: 2016

Journal Articles

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Blood (2016) 128 (22): 3198.

https://doi.org/10.1182/blood.V128.22.3198.3198

Published: 2016

Journal Articles

Synergy: karyotypes and mutations in CLL

Lynne V. Abruzzo

Blood (2016) 128 (3): 319–320.

https://doi.org/10.1182/blood-2016-06-719898

Published: 2016

Journal Articles

MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS

Piyanuch Kongtim, MD, Uday R Popat, MD, Marcos de Lima, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Juliane Chen, Gabriela Rondon, MD, Lynne V. Abruzzo, MD, PhD, Stefan O. Ciurea, MD, Elizabeth J Shpall, MD, Richard E Champlin, MD, Betul Oran, MD

Blood (2013) 122 (21): 3340.

https://doi.org/10.1182/blood.V122.21.3340.3340

Published: 2013

Journal Articles

Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients

Deborah M Stephens, DO, Amy Stark, MAS, William G. Wierda, MD, PhD, Jeffrey A. Jones, MD, MPH, Jennifer A. Woyach, MD, Kami Maddocks, Samantha M. Jaglowski, MD, MPH, Leslie A Andritsos, MD, Joseph M. M. Flynn, DO, MPH, Michael R. Grever, MD, Gerard Lozanski, MD, Constantine S Tam, MBBS, FRACP, FRCPA, MD, Susan O'Brien, MD, Michael J. Keating, MD, Natarajan Muthusamy, DVM, Ph.D, Lynne V. Abruzzo, MD, PhD, Nyla A. Heerema, PhD, John C. Byrd, MD

Blood (2013) 122 (21): 4128.

https://doi.org/10.1182/blood.V122.21.4128.4128

Published: 2013

Journal Articles

Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS

Betul Oran, MD, Piyanuch Kongtim, MD, Marcos de Lima, MD, Uday R Popat, MD, Guillermo Garcia-Manero, Elias J. Jabbour, MD, Lynne V. Abruzzo, MD, PhD, Julianne Chen, Gabriela Rondon, MD, Borje S. Andersson, MD, PhD, Amin Alousi, MD, Stefan O. Ciurea, MD, Elizabeth J Shpall, MD, Richard E Champlin, MD

Blood (2013) 122 (21): 305.

https://doi.org/10.1182/blood.V122.21.305.305

Published: 2013

Journal Articles

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Guillermo Garcia-Manero, MD, Susan O'Brien, M.D., Stefan Faderl, MD, Rajyalakshmi Luthra, Ph.D., William G. Wierda, MD, Ph.D., Alessandra Ferrajoli, Sherry A. Pierce, RN, BS, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2562.

https://doi.org/10.1182/blood.V120.21.2562.2562

Published: 2012

Journal Articles

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

LM Poon, Patricia S Fox, MS, Barry I. Samuels, MD, Susan O'Brien, M.D., Alessandra Ferrajoli, M.D., Michael J. Keating, MD, Elias J. Jabbour, MD, Yvonne Hsu, Lynne V. Abruzzo, MD, PhD, Richard E. Champlin, Roland Bassett, Issa F. Khouri, MD

Blood (2012) 120 (21): 1977.

https://doi.org/10.1182/blood.V120.21.1977.1977

Published: 2012

Journal Articles

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Aziz Nazha, Hagop M. Kantarjian, MD, Preetesh Jain, MD, DM, PhD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, M.D., Rajyalakshmi Luthra, PhD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3757.

https://doi.org/10.1182/blood.V120.21.3757.3757

Published: 2012

NARROW

The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia

Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib

Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia

Intricacies of CLL cytogenetic complexity

Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events

Aberrant Methylation and Decreased Expression of NRIP1 in IGHV -Unmutated CLL

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Synergy: karyotypes and mutations in CLL

MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS

Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients

Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only